What is HC Wainwright’s Estimate for Evotec Q1 Earnings?

Evotec AG (NASDAQ:EVO) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Evotec in a research note issued to investors on Wednesday, April 15th. HC Wainwright analyst S. Ramakanth expects that the company will earn ($0.11) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Evotec’s Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at $0.03 EPS, FY2027 earnings at $0.19 EPS, FY2028 earnings at $0.34 EPS and FY2029 earnings at $0.34 EPS.

Evotec (NASDAQ:EVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 earnings per share for the quarter. The firm had revenue of $297.02 million during the quarter. Evotec had a negative return on equity of 12.40% and a negative net margin of 13.13%.

A number of other research firms have also weighed in on EVO. Berenberg Bank began coverage on Evotec in a research note on Tuesday, February 3rd. They issued a “buy” rating for the company. Wall Street Zen raised Evotec from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.00.

Evotec Stock Performance

NASDAQ EVO opened at $3.15 on Monday. The company has a quick ratio of 1.99, a current ratio of 2.07 and a debt-to-equity ratio of 0.42. The business has a 50-day moving average price of $2.92 and a 200-day moving average price of $3.27. Evotec has a twelve month low of $2.31 and a twelve month high of $4.80.

Hedge Funds Weigh In On Evotec

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd boosted its stake in Evotec by 25.1% during the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock valued at $57,000 after buying an additional 3,709 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after buying an additional 4,600 shares during the last quarter. Bank of America Corp DE boosted its stake in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after buying an additional 9,289 shares during the last quarter. Valeo Financial Advisors LLC bought a new position in Evotec during the second quarter valued at approximately $43,000. Finally, Marshall Wace LLP bought a new position in Evotec during the fourth quarter valued at approximately $40,000. 5.81% of the stock is owned by institutional investors.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.